On November 18, AKESO recorded an Intraday Decline of 4.12% in Regular Trading, trading at HK$60.0 with turnover of HK$176 million.
The clearest recent catalyst is the company’s announcement that its board approved an additional share purchase plan of up to HK$200 million in the open market, to be executed by the trustee of its 2021 restricted share unit scheme and funded by existing cash resources.
The announcement said the board believes the current trading price does not reflect the company’s intrinsic value and growth potential. This followed earlier disclosed market purchases by the trustee on November 16 and November 17 totaling about HK$37 million, including about 336,000 shares for roughly HK$21 million and 250,000 shares for roughly HK$16 million.
The buyback-related support came after sharp volatility triggered by the US FDA complete response letter for ivonescimab’s US filing, an event that had previously driven a steep sell-off and raised uncertainty over the timing of overseas commercialization-related income.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments